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Framingham (16.9%) and the European Hypertension Chart (31.3%). Reasons for 
not using risk tools included time constraints (60.8%), not being convinced of their 
utility (22.1%) and lack of knowledge (20.0%). a high percentage of physicians 
believed the algorithms have limitations (72.4%); 92.1% believed they lead to over-
looking other risk factors and 69.3% believed they cannot be used to calculate risk 
in elderly patients. The most commonly used clinical guidelines were those from the 
ESC (CVD Prevention in Clinical Practice [56.3%] and Management of Arterial 
Hypertension [29.9%]) or from local authorities (17%). In total, 12.9% of physicians 
reported not using guidelines; reasons included the wide choice or uncertainty of which 
to use (47.5%), time constraints (33.7%), lack of knowledge (27.7%) and a perception 
that they are unrealistic (23.8%). CONCLUSIONS: Time constraints, perceived utility 
and inadequate knowledge were common factors limiting the use of cardiovascular 
risk evaluation tools and assessment guidelines. Better compliance with risk assessment 
tools may reduce the high proportion of patients with poorly managed cardiovascular 
risk factors.
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OBJECTIVES: The Adult Treatment Panel III guidelines suggest that the goal of low-
density lipoprotein cholesterol (LDL-C) in patients with both cardiovascular disease 
and diabetes is <100 mg/dL. Many patients remain poorly controlled despite various 
interventions in primary care, including statin therapy and health behavior modiﬁ ca-
tion. We evaluated the impact of adding a clinical pharmacist intervention to usual 
care on LDL-C control and treatment costs in diabetic cardiac patients. METHODS: 
We prospectively compared a clinical pharmacist intervention in 138 patients with a 
matched control sample of 353 patients receiving usual care in Maccabi Healthcare 
Services (MHS) in Israel. Patients with cardiovascular disease and diabetes and LDL-C 
levels >100 mg/dL were identiﬁ ed from the MHS’s computerized database. The clinical 
pharmacist reviewed patients’ clinical charts and discussed the recommendations to 
improve hyper-lipidemic control with the patients’ primary-care practitioners. The 
recommendations were given every three months for a one-year period. The primary 
clinical endpoint was reaching LDL-C goal. Clinical outcomes and overall treatment 
costs in both groups were evaluated at the end of the study year. RESULTS: During 
the study year, 67% of the patients in the intervention group reached the LDL goal 
vs. only 54% in the control group (p = 0.014). LDL target was reached three months 
earlier in the intervention group as compared with control patients (0.710 year vs. 
0.992 year, respectively; log-rank test: p = 0.015). However, at the end of the study 
year, LDL target was maintained in approximately 50% of patients in both groups. 
Overall treatment costs (physician visits, hospital and emergency room admissions, 
lab tests, medications) were 14% lower in the intervention group and 11% higher in 
the control group as compared to the year prior the intervention. CONCLUSIONS: 
A clinical pharmacist intervention in high-risk patients may result in clinical improve-
ments and lower treatment costs. These results demonstrate the high-value of clinical 
pharmacist involvement in patient treatment.
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EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK 
PATIENTS: DISEASE PREVENTION AND MANAGEMENT IN USUAL 
DAILY PRACTICE—TURKISH RESULTS OF EURIKA STUDY
Abaci A
Gazi University, Ankara-on behalf of EURIKA Study Group, Turkey
OBJECTIVES: To assess management of cardiovascular risk factors (CVRF) in daily 
clinical practice and to identify areas of potential improvement in primary prevention 
of CVD. METHODS: A total 663 patients >50 years of age (59.4 ± 7.6 years; 47.2% 
males) with at least one additional CVRF and 67 physicians (mean age: 40.7 ± 8.6 
years; 82.1% males) were included from Turkey in the multicentre, multinational, 
cross-sectional epidemiological EURIKA study (NCT00882336) conducted across 
Europe. Management and control of classical, emergent and psycho-social CVRF, use 
of CV risk assessment by the physicians as well as barriers for estimating and using 
global cardiovascular risk scores were identiﬁ ed. RESULTS: Total CV risk assessment 
in Turkish patients was stated to be performed by 48.5% of the physicians mostly by 
chart (71.9%) and mainly for an advice on healthy lifestyle (84.4%) and to decide on 
antihypertensive (78.1%) or lipid-lowering treatment (75.0%). Time constraint for 
global CV risk evaluation was the main reason (73.5%) for the lack of assessment 
identiﬁ ed by the physicians. a total of 514 patients (77.5%) were classiﬁ ed to have 
high CV risk by the physicians using a local (7.6%) or the recent European Guidelines 
on Cardiovascular Disease Prevention in Clinical Practice (ESC 2007) (80.0%). 
Although global cardiovascular risk was said to be under control in 75.5% of the 
patients, satisfying control of CV risk factors was evident in only 56.7% while the 
overall percentage of the patients who were aware of their CV risk was 69.5%. 
CONCLUSIONS: Apparently targets deﬁ ned in guidelines are not sufﬁ ciently met and 
there is clear need for better management of high risk patients. Development of better 
structured and more realistic, simple and credible national guidelines adapted to suit 
local medical and economic conditions should be encouraged.
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OBJECTIVES: To analyze the impact of regional measures in the sales of the renin-
angiotensin system antagonists in Spain. METHODS: Regional measures from each 
of the 17 Spanish Autonomous Regions (AR) were identiﬁ ed by searching on health 
services’ websites. a Regional Measurement Scale (RMS) in rational use of drugs 
(RUD) was constructed. Values ranged from 0 to 24 considering the number and the 
speciﬁ city of the applied politics. The 2009 market share of the Angiotensin-II Recep-
tor Antagonists (AIIRA) vs. Angiotensin-Converting Enzyme (ACE) inhibitors was 
analyzed. AR market shares and RMS correlations were calculated. Correlated AR 
Market shares were adjusted according to the values of RMS using a linear regression 
model for the AR with correlation between the RMS and the market shares. The 
decrease in market share on the AIIRA by RMS point was determined by the slope 
coefﬁ cient of the regression (β). RESULTS: Health plans, clinical guidelines, pharma-
cotherapeutic guides, health technology assessments and therapeutic newsletters, pro-
moting the prescription of ACE inhibitors rather than AIIRA, were identiﬁ ed. In 14 
out of 17 AR, the correlation between the RMS and the market shares was statistically 
signiﬁ cant (r = 0.55, p = 0.004). Of these, three AR scored 0, ﬁ ve 1 to 10, four 10 to 
20, and two 22 and 23 points respectively. a 0.52% decline in the market share AIIRA 
was observed for each point in the RMS. The maximum impact observed in the market 
share was 11.96%. Considering that the variability in the AIIRA market share was 
24.1%, half of it was explainable by the establishment of RUD measures. CONCLU-
SIONS: Results support the fact that not only the establishment of regional measures 
is important but also the way they are implemented.
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OBJECTIVES: Interest in cardiovascular diseases (CVD) in patients with schizophre-
nia has recently become growing among psychiatrists due to its documented incre-
mental mortality for these causes. Identiﬁ cation of markers for such disorders seems, 
therefore, reasonable. Serum Protein-C-Reactive (PCR) levels have been determined 
as a marker of inﬂ ammation in individuals with CVD and/or at high risk for develop-
ing it. However, it is unknown the role of this protein in schizophrenics. Thus, the 
goal of this research was to explore the use of PCR as a marker of inﬂ ammation and 
CVD in patients with Schizophrenia. METHODS: A cross-sectional analysis of the 
BSA administrative claim database was conducted including all men and women, >18 
years, with a schizophrenia spectrum disorders (by DSM-IV criteria) diagnosis. PCR 
measurement together with socio-demographics, evolution, medical history, 10-years 
CVD risk (Framingham equation) and biochemistry data was extracted for analysis. 
RESULTS: A total of 705 patients [53.0% men, 48.2 + 15.8 years (mean + SD), 5.9 
+ 3.2 years of evolution, 79.7% on atypical drugs] met criteria for analysis. Mean 
10-year CVD risk was high; 11.9% + 5.7% and mean PCR levels were 2.6 + 2.5 mg/L 
with 30.4% showing values above normal’s (>3 mg/L). Unadjusted PCR slightly cor-
related with CVD risk; r = 0.171, P < 0.001. After adjusting by age, sex, evolution, 
smoking and anti-inﬂ ammatory drugs treatment, PCR was linearly associated with 
10-year CVD risk stratiﬁ ed by its level of risk (low, moderate, high/very high); respec-
tively, 2.3 (95% CI: 2.1–2.5), 3.1 (2.6–3.5) and 3.7 (3.2–4.1) mg/L; F = 13.5, P < 
0.001. Patients with known CVD showed also higher PCR levels; 3.7 (2.9–4.5) vs. 
2.5 (2.4–2.7) mg/L, p = 0.008, and higher probability of values above normal’s; Odds 
Ratio = 4.71 (2.01–11.04), P < 0.001. CONCLUSIONS: High PCR levels (above 
normals) were associated with both known CVD and high/very high 10-year risk of 
CVD event in patients with schizophrenia. Then, PCR might be a marker of inﬂ am-
mation and CVD in this psychiatric disorder.
PCV126
USE OF PROTON PUMP INHIBITORS (PPIS) IN ACUTE CORONARY 
SYNDROME PATIENTS TREATED WITH CLOPIDOGREL IN GERMANY, 
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OBJECTIVES: There is controversy in the literature regarding the effects of concomi-
tant use of proton-pump inhibitors (PPIs) potentially reducing the clinical effectiveness 
of clopidogrel. Also in question is whether the effect occurs with all PPIs or only 
omeprazole The purpose of this study is to assess the usage of PPIs in combination 
with clopidogrel in Acute Coronary Syndrome (ACS) patients in the primary care 
setting. METHODS: This was a retrospective study using IMS Disease Analyzer 
databases in France, Germany and the UK. These longitudinal patient databases 
provide information from continuing physician and patient interaction on consulta-
tions, diagnoses and treatments within primary care. RESULTS: From April 2008 to 
April 2009, 57% of post-ACS clopidogrel patients also had a PPI prescribed (France 
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54% and Germany 45%). An overall increase in co-prescribing of clopidogrel and 
PPIs was observed in all countries from April 2006 to April 2009 except for France 
where omeprazole co-prescribing decreased in 2008–2009. The most frequently pre-
scribed PPI in combination with clopidogrel was omeprazole in all three countries 
(58% in the UK, 36% in France and 65% in Germany) The second most frequently 
used PPI was lansoprazole in the UK (36%), pantoprazole in Germany (21%) and 
esomeprazole in France (28%). The proportion of clopidogrel patients who were 
co-prescribed lansoprazole was 36% in the UK and only 11% in France and 2% in 
Germany. CONCLUSIONS: Overall prescribing of PPIs with clopidogrel after ACS 
is common in the UK, France and Germany. Since the publication of the OCLA study 
in 2008 no decrease in concurrent prescribing of clopidogrel and omeprazole was 
observed except in France. Revisions of national guidelines and the clopidogrel label 
in 2009 may further affect prescribing of PPIs, and especially omeprazole, with clopi-
dogrel in the future.
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INCREASING NURSE STAFFING LEVELS IN BELGIAN CARDIAC 
SURGERY CENTERS: A COST-EFFECTIVE PATIENT SAFETY 
INTERVENTION?
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OBJECTIVES: A previous study indicated that increasing nurse stafﬁ ng levels in 
Belgian general cardiac postoperative nursing units was associated with lower mortal-
ity rates. The aim of this study is to conduct a cost-effectiveness analysis of increasing 
nurse stafﬁ ng levels to the level of the 75th percentile in Belgian general cardiac post-
operative nursing units from a hospital perspective. METHODS: The intervention was 
an increase in the number of nursing hours per patient day to the 75th percentile for 
nursing units staffed below that level. The comparator was a “do nothing” alternative. 
Data on nurse stafﬁ ng levels were extracted from the Belgian Nursing Minimum Data 
set and data on in-hospital mortality from the Belgian Hospital Discharge Database. 
The number of life-years gained was calculated by multiplying the number of avoided 
deaths by the life expectancy of patients having a coronary artery bypass graft and 
patients having heart valve procedures. To this effect, survival rates were derived from 
the literature. National cost estimates for the year 2007 were used. Results were 
expressed in the form of the additional costs per avoided death and the additional 
costs per life-year gained. RESULTS: The costs of increasing nurse stafﬁ ng levels to 
the 75th percentile in Belgian general cardiac postoperative nursing units amounted to 
c1,211,022. Such nurse stafﬁ ng levels would avoid an estimated number of 45.9 (95% 
CI: 22.0–69.4) patient deaths per year and generate 458.86 (95% CI: 219.93–693.79) 
life-years gained annually. This corresponds with incremental cost-effectiveness ratios 
of c26,372 per avoided death and c2,639 per life-year gained. Sensitivity analyses 
indicated that the incremental cost-effectiveness ratio was robust to changes in input 
parameters. CONCLUSIONS: Increasing nurse stafﬁ ng levels appears to be a cost-
effective intervention as compared to other cardiovascular interventions.
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MODELING OF HEALTH SERVICE RESEARCH RESULTS WITH UPDATED 
COST DATA—THE GERSHWIN STUDY EXAMPLE
Brüggenjürgen BH, Willich SN, McBride D
University Medicine Berlin, Charité, Berlin, Berlin, Germany
OBJECTIVES: Health services research is an expanding ﬁ eld of interest for recently 
introduced medical technologies. Complementing efﬁ cacy results with effectiveness 
data illustrates the clinical contribution of a new technology in the real-life setting. 
With effectiveness results being relatively stable over time, the change in reimburse-
ment and price decreases have a substantial impact on initial cost-effectiveness con-
siderations. The three-year GERSHWIN study (GERman Stent Health outcomes 
WIthin Normal practice) was designed to determine long-term clinical outcome and 
economic consequences of Sirolimus-eluting stents (SES) versus bare-metal stents BMS 
in the treatment of CAD from a societal prospective. Economic analysis resulted in 
an ICER of c29,868 per avoided major adverse coronary events (MACE) based on 
2003 to 2005 prices. Due to substantial price reductions, a remodelling with current 
prices would increase applicability of results by decision-makers. METHODS: Com-
plete intention-to-treat study data were valued and analyzed with 2009 prices for the 
main cost drivers (hospital case rate, incremental stent cost and generic clopidogrel 
price). Sensitivity analyses were conducted to evaluate the robustness of the results 
and included a low- and high-cost scenario. RESULTS: Initial hospitalization costs 
were c1157 higher per patient receiving SES, driven primarily by the incremental 
acquisition cost for SES compared BMS. Follow-up direct costs were similar in both 
groups of patients, however the indirect costs in SES patients were signiﬁ cantly lower. 
Overall 36-month MACE-related costs were c283 not signiﬁ cantly higher in the SES 
group (p = 0.62). The ICER based on 2009 cost data resulted in c5320 per MACE 
avoided. Variation of incremental SES prices between c650 and c750 showed no 
signiﬁ cant impact. CONCLUSIONS: Incorporating updated cost data can drastically 
change the ICER generated from health services research projects. Modelling with 
current cost data is an essential contribution for iterative cost-beneﬁ t assessment 
procedures.
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TELEHEALTH—EARLY EVALUATION FINDINGS
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OBJECTIVES: NHS North Yorkshire and York commissioned York Health Econom-
ics Consortium to carry out an evaluation of their recent Telehealth pilot involving 
patients with long-term conditions. The ﬁ ndings from the evaluation will be used to 
inform plans for the further rollout of Telehealth in North Yorkshire. METHODS: 
Three approaches were employed: a questionnaire was used to obtain details about 
the Telehealth experiences of users and their carers; Case Managers and Community 
Matrons with Telehealth patients on their caseloads were interviewed about referral 
criteria and the impact of Telehealth on their role and patient care; Health care 
resource use data were analyzed. Some caution should be used when generalizing 
ﬁ ndings due to the small sample size and the speciﬁ c characteristics of pilot Telehealth 
recipients. RESULTS: Forty-eight questionnaires were handed out and twenty 
returned (42%). Overall, respondents were happy with Telehealth (90%). Results 
showed that the installation process had been smooth (75%); individuals had received 
sufﬁ cient tuition (95%); they were conﬁ dent using the equipment (95%); and were 
happy with the service received from the monitoring centre (95%). Telehealth gave 
users peace of mind and helped them to manage their own health condition. However, 
a number of users had experienced technical issues (during installation and when 
taking daily measurements). Although there had been some teething problems, mainly 
in relation to the installation process and the monitoring system, clinicians were 
broadly supportive of Telehealth. There was a repeated view that individual patient 
characteristics needed to be taken into account when identifying patients who would 
beneﬁ t from Telehealth. The impact of Telehealth on health care resource use was 
difﬁ cult to determine within the eight month timescale of the pilot. CONCLUSIONS: 
Telehealth gives users peace of mind and helps them manage their health; however, 
its impact on health care resource use is still unclear.
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PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY 
SYNDROME PATIENTS IN 2008–2009: BASELINE RESULTS FOR AUSTRIA 
FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II 
(APTOR II)
Ammer M1, Paget MA2, Hronkova M3, Norrbacka K4, Eber B1
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Austria, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international, pro-
spective, observational study recruited ACS patients in selected hospitals undergoing 
percutaneous coronary intervention (PCI), April 2008–March 2009, capturing prac-
tice patterns, resource use and QoL. RESULTS: A total of 148 ACS-PCI patients (out 
of the 152 recruited) were eligible: median age 60 yrs (IQR 51–69), median weight 
80 kg (IQR 70–89), 20% female, 28% Type II diabetics, and 17% prior myocardial 
infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/
NSTEMI)-44% and ST-elevation MI (STEMI)-56%. Almost all patients (96%) 
received stents: 28% bare metal stents only, 70% drug eluting stents only and 2% 
both. Time from start of ACS symptoms to PCI was ≤3 days in 86% of UA/NSTEMI 
patients and ≤1 day in 98% of STEMI patients. Oral antiplatelet medications with 
loading dose (LD) used: aspirin-97% and clopidogrel-91%. Clopidogrel LD was 
administered in the ambulance-9%, previous hospital-10%, emergency room-41%, 
CCU or ICU-31%, catheterization lab-5%, or other ward-5%. LD was administered 
between 6 hours before to 6 hours after PCI in 82% of cases. The ﬁ rst clopidogrel 
LD was 600 mg in 85% and 300 mg in 10% of cases and in-hospital maintenance 
dose was 75 mg in 97%. At time of hospital discharge, 97% of the discharged patients 
were prescribed clopidogrel (discharge dose 75 mg for all patients except one). QoL 
in discharged patients was good: median EQ-5D health state index at 1.00 (IQR 
0.81–1.00). CONCLUSIONS: These real life data reﬂ ect treatment patterns among 
ACS patients managed by PCI in selected hospitals in Austria in 2008–2009. Timing 
and place of loading of antiplatelet agents differ. The QoL of patients at discharge 
was high.
PCV131
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STENT TYPE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE 
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ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for patients with acute coronary syndrome (ACS); 
however, reimbursement for antiplatelet therapy differs by EU country and is depen-
dent upon the use of bare metal (BMS) or drug-eluting (DES) stents during percutane-
ous coronary intervention (PCI). Dual antiplatelet (clopidogrel + aspirin) treatment 
